about
Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to dateDiabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetesInhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitusUse of QT intervals for a more accurate diagnose of syncope and evaluation of syncope severity.Neuron protection as a therapeutic target in acute ischemic stroke.Diabetic foot syndrome as a possible cardiovascular marker in diabetic patients.Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver DiseasePeripheral frequency of CD4+ CD28- cells in acute ischemic stroke: relationship with stroke subtype and severity markersImmune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.Inflammatory cytokines in acute ischemic stroke.Arterial stiffness, endothelial and cognitive function in subjects with type 2 diabetes in accordance with absence or presence of diabetic foot syndrome.Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke with and without metabolic syndrome.Inflammation as a therapeutic target in acute ischemic stroke treatment.Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation.Effects of physical exercise on inflammatory markers of atherosclerosis.Supraventricular tachycardias: proposal of a diagnostic algorithm for the narrow complex tachycardias.Electrocardiographic diagnosis of atrial tachycardia: classification, P-wave morphology, and differential diagnosis with other supraventricular tachycardias.New insights about the putative role of myokines in the context of cardiac rehabilitation and secondary cardiovascular prevention.MANAGEMENT OF BLOOD PRESSURE AND HEART RATE IN PATIENTS WITH ACUTE STROKE.Education and hypertension: impact on global cardiovascular risk.Relationship Between Ambulatory Arterial Stiffness Index (Aasi) And Night/Day Blood Pressure Ratio In Essential hypertensives.Are the Myokines the Mediators of Physical Activity-Induced Health Benefits?Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases.MicroRNA and receptor mediated signaling pathways as potential therapeutic targets in heart failure.IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine.Sodium thiosulfate not always resolves calciphylaxis: an ambiguous response.Changes in natriuretic peptide and cytokine plasma levels in patients with heart failure, after treatment with high dose of furosemide plus hypertonic saline solution (HSS) and after a saline loading.Fetuin-A and CD40 L plasma levels in acute ischemic stroke: differences in relation to TOAST subtype and correlation with clinical and laboratory variables.[Role of combination NK/KIRs in the natural history of viral infections.]Association between low education and higher global cardiovascular risk.Developing drug strategies for the neuroprotective treatment of acute ischemic stroke.Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction.Circulating adiponectin: a cardiometabolic marker associated with global cardiovascular risk.Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson-Fabry disease.Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.Insulin resistance and glomerular hemodynamics in essential hypertension.Predictors of outcome in acute ischemic cerebrovascular syndromes: The GIFA study.Identification of a novel mutation in the alpha-galactosidase A gene in patients with Fabry disease.Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events.Calcium channel blockers and peripheral arterial flow in normal and in hypertensive subjects.
P50
Q27001147-E3877231-D09C-4399-B2B3-BBB9689691B3Q28082521-4F97918A-D352-4B34-B3D6-25C7DB9A296FQ28193333-2BAF9699-8BC2-4FC1-B743-B212F613B51EQ33163860-03284876-8324-4220-AD2C-E9538BD29C48Q35009080-CEAE92D3-150E-4592-85D0-3071586ED7F1Q35342114-4918F090-4A33-4C1D-B41D-C25AC3E3FDC1Q35870004-34376AE9-2A3E-4F8A-9C47-554E6D70B20CQ36152969-262797C5-0750-498F-BD33-C7AB8F2AE637Q36219910-59CDFA62-677B-4BF8-8920-1EEFB0993DCEQ37347436-CCE775BA-80AF-48CE-8590-2E66EDE83BFBQ37565982-B1C54B55-3B31-4C1C-AF54-4D8527B4117AQ37617485-A87A9CFD-9E76-431F-BFD2-3A3508708B74Q37619626-C567437F-CFD6-4DF0-AF9F-E338D78EE6EEQ37979302-8B5154BE-1055-4BEE-8D74-3C71F78E018CQ37990568-2097BFC3-EC50-499D-B10D-4561FD8ED10FQ38087723-659EDA37-3D63-4B1E-9F59-019C9DCFF7B7Q38296344-97AA6192-8268-4145-9A48-589DF312F434Q38635300-A9BBD6CA-666F-4EC3-847C-34457FDA9014Q38656640-75320F73-0C24-465C-AFE9-7677E6CB51FEQ38705197-8C5B8BEF-8304-4F62-B148-A2B6E5BDD6AFQ38715251-B57D1E3B-5C38-4199-92C0-9BA252E12DD1Q38822154-353FA385-B52B-43D1-912B-7D17D88C4B1CQ38830095-FE537393-4E16-465C-A378-B50518E1CBD2Q38842507-BC82812C-ADDB-4FF3-81D3-342EAE2319A2Q38993476-476F20A1-19D4-41A9-A020-9122F44D224BQ39273414-532D3F5A-BD2E-4B65-867A-790AB7229FD7Q39288641-69E8E1DE-44EA-47C9-9ED2-636E2EE7E9AFQ39952070-3CAB9E3D-79BA-4CB9-9082-226D58486086Q40068301-CCAF7D35-30FE-4A9B-A54E-262CD636EDF4Q40258617-CDCF7771-F2CD-469C-9368-42A1E9FCFE4DQ40429078-BE953F2A-3929-48CC-B07A-39D8C31E870DQ40875896-50E36DA2-DF1E-467A-96E8-FAC8791D5515Q41618523-EFF7635A-185B-46FC-95B9-AF1F8B29D14DQ42233423-802B7ACC-8BB7-45C3-84BE-B923B393AE2FQ42689998-6FEDA49A-9974-4799-AD21-E2B8392B6773Q44091698-C0F4C1FA-4445-4E18-A1FE-7178833C8FC2Q44276792-1982D6C1-21D3-4276-A36D-52637F55AE0CQ44801556-7E4ADC3F-3F09-4005-A08C-9DAFAFC8BDF4Q45156380-846E2C98-2B7C-41E3-9981-D646BA51A883Q45252536-96D841D7-6422-4C65-9DF3-EAB530F2239D
P50
description
investigador
@es
researcher ORCID ID = 0000-0002-8083-3699
@en
wetenschapper
@nl
name
Antonio Pinto
@ast
Antonio Pinto
@en
Antonio Pinto
@es
Antonio Pinto
@nl
Antonio Pinto
@sl
type
label
Antonio Pinto
@ast
Antonio Pinto
@en
Antonio Pinto
@es
Antonio Pinto
@nl
Antonio Pinto
@sl
prefLabel
Antonio Pinto
@ast
Antonio Pinto
@en
Antonio Pinto
@es
Antonio Pinto
@nl
Antonio Pinto
@sl
P106
P1153
35270127400
P21
P31
P496
0000-0002-8083-3699
P569
2000-01-01T00:00:00Z